Published in Virology on June 15, 1996
Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol (2005) 2.08
Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol (2006) 1.80
Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: cis-acting requirements for replication and ori-Lyt-associated RNA transcription. J Virol (2004) 1.48
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains two functional lytic origins of DNA replication. J Virol (2002) 1.46
Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein-Barr virus replication gene mRNA. J Virol (1998) 1.46
The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol (1998) 1.31
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol (1998) 1.30
Human cytomegalovirus DNA replication requires transcriptional activation via an IE2- and UL84-responsive bidirectional promoter element within oriLyt. J Virol (2004) 1.16
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication. J Virol (2004) 1.15
Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells. J Virol (2003) 1.12
Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol (2010) 1.09
Interaction with the Epstein-Barr virus helicase targets Zta to DNA replication compartments. J Virol (2001) 1.09
Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol (2013) 1.04
Identification of bZIP interaction partners of viral proteins HBZ, MEQ, BZLF1, and K-bZIP using coiled-coil arrays. Biochemistry (2010) 1.00
A particular DNA structure is required for the function of a cis-acting component of the Epstein-Barr virus OriLyt origin of replication. Nucleic Acids Res (1997) 0.97
The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex. J Virol (2000) 0.96
Biophysical analysis of natural variants of the multimerization region of Epstein-Barr virus lytic-switch protein BZLF1. J Virol (2001) 0.96
Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol (2012) 0.95
Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol (2012) 0.95
Atypical bZIP domain of viral transcription factor contributes to stability of dimer formation and transcriptional function. J Virol (2007) 0.95
Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1. J Virol (2009) 0.93
Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med (2014) 0.93
Low level of lytic replication in a recombinant Epstein-Barr virus carrying an origin of replication devoid of BZLF1-binding sites. J Virol (2004) 0.90
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes. J Virol (2007) 0.86
Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J Virol (2012) 0.85
Mutations of amino acids in the DNA-recognition domain of Epstein-Barr virus ZEBRA protein alter its sub-nuclear localization and affect formation of replication compartments. Virology (2008) 0.84
A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein. PLoS Pathog (2010) 0.84
Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA. J Virol (1997) 0.83
Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism. Future Virol (2010) 0.82
Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol (2010) 0.81
Replication of Epstein-Barr viral DNA. Cold Spring Harb Perspect Biol (2013) 0.80
Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation. Clin Exp Immunol (1999) 0.79
Evolutionary aspects of oncogenic herpesviruses. Mol Pathol (2000) 0.79
Transcriptional repression of K-Rta by Kaposi's sarcoma-associated herpesvirus K-bZIP is not required for oriLyt-dependent DNA replication. Virology (2007) 0.78
Identification and Characterization of the Physiological Gene Targets of the Essential Lytic Replicative Epstein-Barr Virus SM Protein. J Virol (2015) 0.77
Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients. J Immunol Res (2016) 0.75
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A (1998) 5.37
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J (2000) 3.52
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J (1997) 2.87
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J (2001) 2.46
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J Virol (1995) 2.45
Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J (1997) 2.38
Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J (1999) 2.09
Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol (2000) 2.04
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A (2002) 1.99
A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J (1993) 1.96
Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol (1997) 1.90
cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J Virol (1993) 1.80
Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines. J Virol (1993) 1.56
Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.54
Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J (1996) 1.53
Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood (1997) 1.47
Latent Marek's disease virus can be activated from its chromosomally integrated state in herpesvirus-transformed lymphoma cells. EMBO J (1993) 1.44
TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J (2001) 1.42
Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA. J Virol (1995) 1.35
Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol (1998) 1.30
Status of Marek's disease virus in established lymphoma cell lines: herpesvirus integration is common. J Virol (1993) 1.27
Immortalization of human primary B lymphocytes in vitro with DNA. Proc Natl Acad Sci U S A (1995) 1.22
Cellular transcription factors recruit viral replication proteins to activate the Epstein-Barr virus origin of lytic DNA replication, oriLyt. EMBO J (1999) 1.21
LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J (1999) 1.21
Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol (1998) 1.19
A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.16
Cellular proteins bind to the downstream component of the lytic origin of DNA replication of Epstein-Barr virus. J Virol (1995) 1.13
The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol (2000) 1.10
Rapid proliferation of B cells from adenoids in response to Epstein-Barr virus infection. Cancer Res (1996) 1.08
Plasmid-like replicative intermediates of the Epstein-Barr virus lytic origin of DNA replication. J Virol (1996) 1.06
Short repeats cause heterogeneity at genomic terminus of bovine herpesvirus 1. J Virol (1986) 1.03
The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol (1996) 1.01
Spontaneous activation of the lytic cycle in cells infected with a recombinant Kaposi's sarcoma-associated virus. J Virol (2001) 0.99
Genomic termini of equine herpesvirus 1. J Virol (1990) 0.98
Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell Mol Life Sci (2004) 0.90
The PKC targeting protein RACK1 interacts with the Epstein-Barr virus activator protein BZLF1. Eur J Biochem (2000) 0.90
c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo. Oncogene (1996) 0.85
Characterization of the BNLF-1 oncogene of Epstein-Barr virus. Curr Top Microbiol Immunol (1989) 0.83
Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. J Gene Med (2000) 0.82
Genetic design of an optimized packaging cell line for gene vectors transducing human B cells. Gene Ther (2006) 0.81
Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Gene Ther (2006) 0.78
Chimeric and mutated variants of LMP1. A helpful tool to analyze the structure-function relationship of a pseudoreceptor. Methods Mol Biol (2001) 0.78
Rapid method for the identification and screening of herpesviruses by DNA fingerprinting combined with blot hybridization. J Virol Methods (1986) 0.76
[Immunity of the skin--infection and percutaneous immunization of rabbits with E. coli ATCC 13676]. Zentralbl Bakteriol Mikrobiol Hyg A (1985) 0.75
[Pathogenicity of Yersinia enterocolitica from epidemiological viewpoint--review]. Berl Munch Tierarztl Wochenschr (1981) 0.75
[Etiology and immunotherapy of bacterial dermatitis--an experiment]. Berl Munch Tierarztl Wochenschr (1985) 0.75
[Pathogenicity factors in Yersinia enterocolitica from an epidemiological viewpoint--review]. Berl Munch Tierarztl Wochenschr (1981) 0.75
[Plasmid-mediated pathogenicity factors of Yersinia enterocolitica from the epidemiological viewpoint]. Zentralbl Bakteriol Mikrobiol Hyg A (1984) 0.75
Genetic analysis and gene expression with mini-Epstein-Barr virus plasmids. Methods Mol Biol (2001) 0.75